Survival Benefits of CIMP-high Colorectal Cancer Patients on Chemotherapy
Author Information
Author(s): Min Byung-Hoon, Bae Jeong Mo, Lee Eui Jin, Yu Hong Suk, Kim Young-Ho, Chang Dong Kyung, Kim Hee Cheol, Park Cheol Keun, Lee Suk-Hee, Kim Kyoung-Mee, Kang Gyeong Hoon
Primary Institution: Samsung Medical Center, Sungkyunkwan University School of Medicine
Hypothesis
Does the CpG island methylator phenotype (CIMP) status affect the survival of colorectal cancer patients receiving fluoropyrimidine-based adjuvant chemotherapy?
Conclusion
CIMP-high colorectal cancer patients may benefit from fluoropyrimidine-based adjuvant chemotherapy, showing longer recurrence-free survival.
Supporting Evidence
- CIMP-high CRCs showed significantly better recurrence-free survival with chemotherapy compared to surgery alone.
- 34 cases (13.9%) were identified as CIMP-high.
- Patients with CIMP-low/negative CRCs did not show significant differences in recurrence-free survival with or without chemotherapy.
Takeaway
Some patients with a specific type of colorectal cancer (CIMP-high) do better when they get a certain kind of chemotherapy after surgery.
Methodology
245 patients with colorectal cancer were analyzed for CIMP status and their recurrence-free survival was compared based on chemotherapy treatment.
Potential Biases
Potential selection bias due to non-randomized treatment assignment.
Limitations
The sample size for the recurrence-free survival analysis was small and there may be selection bias.
Participant Demographics
245 patients, with a mean age of 59.7 years, including both male and female participants.
Statistical Information
P-Value
0.022
Confidence Interval
95% CI: 1.351-26.314
Statistical Significance
p=0.022
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website